Clinical activity of tipifarnib in hematologic malignancies

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2007-02-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/13543784.16.3.381PMID 17302532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors

  2010cited by this paper
• RAS: Target for Cancer Therapy

  2008cited by this paper
• Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

  2005cited by this paper
• Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

  2005cited by this paper
• Alternate Week Administration of the Farnesyltransferase Inhibitor Tipifarnib (ZARNESTRA®, R115777) in Patients with Myelodysplastic Syndrome: Results of a Phase 1 Study.

  2005cited by this paper
• Tumorigenesis: Flying beneath the radar

  2004cited by this paper
• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

  2004cited by this paper
• Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction Pathway

  2004cited by this paper
• Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

  2004cited by this paper
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

  2004cited by this paper
• Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action

  2004cited by this paper
• Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia.

  2004cited by this paper
• A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia.

  2004cited by this paper
• High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM).

  2004cited by this paper
• In-Vitro Cytotoxicity of Tipifarnib (Zarnestra TM) in Pediatric AML and ALL Samples Is Independent of RAS Mutations.

  2004cited by this paper
• Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.

  2004cited by this paper
• Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

  2004cited by this paper
• A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

  2004cited by this paper
• Analysis of Retroviral Vector Insertion Sites after T-Cell Directed Gene Therapy.

  2004cited by this paper
• IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course during Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation.

  2004cited by this paper
• Farnesyltransferase inhibitors.

  2004cited by this paper
• Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

  2003cited by this paper
• Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

  2003cited by this paper
• Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.

  2003cited by this paper
• Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability.

  2003cited by this paper
• Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss

  2003cited by this paper
• Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

  2003cited by this paper
• Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2002cited by this paper
• RPR‐115135, a farnesyltransferase inhibitor, increases 5‐FU‐ cytotoxicity in ten human colon cancer cell lines: Role of p53

  2002cited by this paper
• Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.

  2002cited by this paper
• The challenge of acute myeloid leukemia in older patients

  2002cited by this paper
• Ras as a target in cancer therapy.

  2002cited by this paper
• Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

  2002cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors

  2001cited by this paper
• A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

  2001cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001influential reference
• Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

  2001cited by this paper
• Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.

  2001cited by this paper
• Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

  2001cited by this paper
• The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

  2001cited by this paper
• Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.

  2001cited by this paper
• Farnesyltransferase inhibitors.

  2001cited by this paper
• Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

  2001cited by this paper
• RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells.

  2001cited by this paper
• The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.

  2001influential reference
• Blocking oncogenic Ras signaling for cancer therapy.

  2001cited by this paper
• Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.

  2001cited by this paper
• FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

  2001cited by this paper
• Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2000cited by this paper
• Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.

  2000cited by this paper
• The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis

  2000influential reference
• Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.

  1999influential reference
• RAS and leukemia: from basic mechanisms to gene-directed therapy.

  1999cited by this paper
• Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

  1999influential reference
• Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression*

  1999cited by this paper
• Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

  1998cited by this paper
• J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.

  1998cited by this paper
• Non-Ras targets of farnesyltransferase inhibitors: focus on Rho

  1998cited by this paper
• Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

  1997cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• Protein Prenylation, et cetera--Signal Transduction in Two Dimensions

  1997cited by this paper
• Cellular transformation and malignancy induced by ras require c-jun

  1996cited by this paper
• Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling.

  1996influential reference
• Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

  1995cited by this paper
• Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.

  1995cited by this paper
• Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*)

  1995influential reference
• Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

  1995cited by this paper
• Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines

  1994cited by this paper
• Ras regulatory interactions: Novel targets for anti‐cancer intervention?

  1994cited by this paper
• Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.

  1993cited by this paper
• ras and human tumors.

  1992influential reference
• Protein prenylation: key to ras function and cancer intervention?

  1992cited by this paper
• ras oncogenes in human cancer: a review.

  1989influential reference
• Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

  1988influential reference
• H-40, an antigen controlled by an Igh linked gene and recognized by cytotoxic T lymphocytes. I. Genetic analysis of H-40 and distribution of its product on B cell tumors

  1984cited by this paper

• Virtual screening and biological evaluation to identify pharmaceuticals potentially causing hypertension and hypokalemia by inhibiting steroid 11β-hydroxylase.

  2023cites this paper
• Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades

  2020cites this paper
• Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.

  2017cites this paper
• In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells

  2016cites this paper
• Advances in paediatric cancer treatment.

  2014cites this paper
• New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

  2012cites this paper
• New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.

  2010cites this paper
• Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

  2010cites this paper
• 71 – Molecular Targeted Therapy

  2010cites this paper
• Targeted therapies in multiple myeloma

  2009cites this paper
• Targeting the mevalonate pathway for improved anticancer therapy.

  2009cites this paper
• Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors.

  2009cites this paper
• Autophagy induced by farnesyltransferase inhibitors in cancer cells

  2008cites this paper
• Principles of Molecularly Targeted Therapy: Present and Future

  2008cites this paper